The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1650
    
   			ISSUE 1650
May 16, 2022
                			
                		 Issue 1650
                		- A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
 - Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
 - Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
 - In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
 - In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
 - Addendum: Dexlansoprazole for GERD
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
May 16, 2022 (Issue: 1650)
				The FDA has licensed PreHevbrio (VBI Vaccines), a
recombinant, 3-antigen, 3-dose hepatitis B vaccine,
for the prevention of infection caused by all known
subtypes of hepatitis B virus (HBV) in adults. It has
been available in Israel since...more
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				